Ovid Therapeutics Inc.
OVIDHealthcare|Biotechnology|US
$2.85
+0.27 (+10.47%)
Tangible Book / Share
$2.85
Cash / Share
$1.59
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04106557 A Study of OV101 in Individuals With Angelman Syndrome (AS) | Primary Disease or Condition Being Studied: Angelman Syndrome (AS) | P3 | Completed | 104 | RCT, Double-blind | Gaboxadol, Placebo |
| NCT03697161 A Study of OV101 in Individuals With Fragile X Syndrome | Fragile X Syndrome (FXS) | P2 | Completed | 36 | RCT, Double-blind | OV101 (gaboxadol) |
| NCT03109756 Single Dose Pharmacokinetic (PK) Study | Angelman Syndrome, Fragile X Syndrome | P1 | Completed | 12 | Open-label | OV101 |